Novocure Awards $250,000 to Support Families First’s New Home

Novocure Awards $250,000 to Support Families First’s New Home

PORTSMOUTH — Novocure, a global oncology company with its U.S. Operations Center in Portsmouth, has pledged $250,000 towards the capital campaign for a new home for Families First Health and Support Center.

The donation, which is campaign’s lead corporate gift, will help turn a former gym on Greenleaf Woods Drive in Portsmouth into a community health center providing medical, dental and behavioral health care; parent and family programs; an in-house pharmacy; and an SOS Recovery Center. Construction is under way, and the move is planned for late 2021.

Above: Novocure Executive Chairman Bill Doyle and Janet Laatsch, CEO of Greater Seacoast Community Health, visit the new Families First building in Portsmouth, which Novocure donated $250,000 to support. 

“Families First and Novocure share an important commitment to meeting the health-care needs of patients, whether in the community health setting or in oncology,” said William Doyle, Novocure’s Executive Chairman. “We are pleased to provide this donation to Families First to help the organization carry out their admirable mission in the Seacoast region.”

Families First is part of Greater Seacoast Community Health, which serves almost 20,000 Seacoast residents annually at three health centers — Families First, Goodwin Community Health and Lilac City Pediatrics — and three SOS Recovery Centers.

More information about Families First’s services and the New Home campaign can be found at or by contacting Joann Neumann, chief development officer, at or (603) 422-8208 ext. 3144.

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields are electric fields that disrupt cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth; Malvern, Pennsylvania; and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. More information is at or @Novocure on LinkedIn and Twitter.

Above: Representatives from Families First, Novocure and WJP Development of Portsmouth gather outside the community health center’s new site to celebrate Novocure’s $250,000 gift to support the project.


Translate »